Abstract Details

Title Neurocognitive Function and Psychiatric Comorbidities in Patients with Epilepsy with Eyelid Myoclonia

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P7 - Poster Session 7 (5:00 PM-6:00 PM)

Poster/Presentation
Number 9-002

Objective The objective of this study was to describe the cognitive functioning and psychiatric comorbidities of patients with epilepsy with eyelid myoclonia (EEM).

Background EEM is a rare childhood-onset epilepsy syndrome characterized by eyelid myoclonia, photosensitivity, and eyelid closure-induced seizures or EEG paroxysms. While normal cognition is reported in many patients, there is limited data about neurocognitive abilities and psychiatric comorbidities in EEM.

Design/Methods A database of 134 patients with EEM was reviewed for patients who underwent neuropsychometric testing. Demographics, types of seizures, antiseizure medications, and psychiatric comorbidities were identified. Psychometric testing included standardized intelligence tests, including the Wechsler Adult Intelligence Scale (4th Ed., WAIS-IV), Wechsler Intelligence Scale for Children (5th Ed., WISC-V)) or Differential Abilities Scale (2nd Ed. DASI-II). Index scores were utilized for descriptive analysis, including the intelligence quotient (IQ), Verbal Comprehension Index (VCI), Perceptual Reasoning Index (PRI) or Visual Spatial Index (VSI), Working Memory Index (WMI), and Processing Speed Index (PSI). Scores were documented as standard scores (SS) with a mean of 100 and standard deviation of 15. IQ scores were categorized as low average and above (SS = 80-130) and below average (SS<80).

Results Fifteen patients (13 females, 86.7%) underwent neuropsychometric testing. Median age of epilepsy onset was 4 (range 1-14), and median age at neuropsychometric testing was 17 (range 7-22). Median IQ was 84 (range 56-110); 7 patients had below average IQ. Other median results of neuropsychometric measures were: VCI 93 (range 69-116), PRI/VSI 82 (range 67-115), WMI 78.5 (range 54-100), and PSI 84 (range 70-100). The most common psychiatric comorbidities were anxiety (N=10), depression (N=7), ADHD (N=6), and autism (N=2).

Conclusions

A wide range of neurocognitive abilities was found among EEM patients. Psychiatric comorbidities were common. Identifying cognitive impairment and psychiatric comorbidities in EEM is crucial to implement appropriate management strategies.

Authors/Disclosures
Hannah Padilla PRESENTER	Miss Padilla has nothing to disclose.
Eva Alden, PhD	Dr. Alden has nothing to disclose.
Isha Snehal, MBBS	Dr. Snehal has nothing to disclose.
Jeffrey W. Britton, MD, FAAN (Mayo Graduate School of Medicine)	Dr. Britton has received personal compensation in the range of $0-$499 for serving as a Online course with American Clinical Neurophysiology Society.
Lily Wong-Kisiel, MD, FAAN (Mayo Clinic)	Dr. Wong-Kisiel has nothing to disclose.
Elaine C. Wirrell, MD, FAAN (Mayo Clinic/Dept of Child Neurology)	Dr. Wirrell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biocodex. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Encoded. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRIN. Dr. Wirrell has received publishing royalties from a publication relating to health care.
Kelsey M. Smith, MD (Mayo Clinic)	The institution of Dr. Smith has received research support from CURE Epilepsy. The institution of Dr. Smith has received research support from UCB Pharmaceuticals.

��ɫ��

��ɫ��